Directory
>
Colin Hessel
Colin Hessel
Executive Vice President, Development Operations | Ambrx
United States
Colin Hessel
Summary
Colin Hessel is a seasoned drug development executive and biostatistician with a robust 25-year track record in the pharmaceutical industry, particularly in oncology. His leadership skills are complemented by a strong background in clinical trial design and regulatory strategy, having successfully led teams of over 200 professionals in the development of groundbreaking therapies. Colin played a pivotal role in the approval of cabozantinib across multiple indications, showcasing his expertise in navigating complex regulatory environments. His innovative spirit is evident in his invention of the 'trial in a trial' study design, aimed at enhancing clinical trial robustness. With a commitment to fostering transformational leadership, he is dedicated to building high-performing teams that align with organizational missions. Colin's academic foundation includes advanced degrees from the University of Southern California, further solidifying his expertise in biostatistics and clinical research. He is passionate about advancing oncology therapies and enhancing patient outcomes through rigorous data-driven strategies.
Colin Hessel
Work Experience
Executive Vice President, Development Operations at
Ambrx
March 2023 - Present
Biostatistics & Drug Development Consultant at
Self-Employed
August 2022 - March 2023
Senior Vice President, Development Operations at
Exelixis
January 2016 - July 2022
Vice President, Development Operations at
Exelixis
January 2015 - January 2016
Vice President and Head, Biostatistics and Clinical Data Management at
Exelixis
January 2012 - January 2015
Executive Director & Head, Biostatistics and Clinical Data Management at
Exelixis
January 2009 - January 2012
Senior Director & Head, Biostatistics and Clinical Data Management at
Exelixis
January 2008 - January 2009
Director & Head, Biostatistics and Clinical Data Management at
Exelixis
April 2007 - January 2008
Associate Director, Biostatistics at
Telik
January 2005 - March 2007
Director, Biostatistics at
MedImmune
January 2002 - January 2004
Associate Director, Biostatistics at
MedImmune
January 1998 - January 2002
Biostatistician at
Amgen
January 1996 - January 1998
Colin Hessel
Education
Keck School of Medicine of the University of Southern California, Master Of Science
January 1970 - January 1970
Keck School of Medicine of the University of Southern California, Master Of Science
January 1970 - January 1970
University of California, Irvine, Bachelors
January 1970 - January 1970
University of Southern California, Master Of Science
Frequently Asked Questions about Colin Hessel
What is Colin Hessel email address?
Colin Hessel's primary email address is ************@exelixis.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Colin Hessel work for?
Colin Hessel is a Executive Vice President, Development Operations at Ambrx, a company specializing in Commercial physical research.
Where Colin Hessel graduated from?
Colin Hessel holds a degree in Masters from Keck School of Medicine of the University of Southern California.
How can I directly contact Colin Hessel?
To contact Colin Hessel directly, you can use the email address ************@exelixis.com. Complete contact information is available upon registration with Muraena.
Who is Colin Hessel?
Colin Hessel is a seasoned drug development executive and biostatistician with a robust 25-year track record in the pharmaceutical industry, particularly in oncology. His leadership skills are complemented by a strong background in clinical trial design and regulatory strategy, having successfully led teams of over 200 professionals in the development of groundbreaking therapies. Colin played a pivotal role in the approval of cabozantinib across multiple indications, showcasing his expertise in navigating complex regulatory environments. His innovative spirit is evident in his invention of the 'trial in a trial' study design, aimed at enhancing clinical trial robustness. With a commitment to fostering transformational leadership, he is dedicated to building high-performing teams that align with organizational missions. Colin's academic foundation includes advanced degrees from the University of Southern California, further solidifying his expertise in biostatistics and clinical research. He is passionate about advancing oncology therapies and enhancing patient outcomes through rigorous data-driven strategies.
Colin`s contact details
************@exelixis.com
************@ambrx.com
Colleagues
Chief Scientific Officer and GM China
Executive Director, Regulatory Affairs
Chief Regulatory Officer
President and Chief Executive Officer
Executive Vice President; Head of Clinical
Chief Financial Officer
Vice President, Pharmaceutical & Analytical Development at Ambrx, a Johnson & Johnson Co.
VP, Head of Medical Affairs